Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15766535 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL15766252 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL15766679 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL15766251 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL6949696 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL15766492 | 1.00 | DNM1 (0.48) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL6546840 | 0.98 | DNM1 (0.44) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL498120 | 0.91 | — | — | |
| SCHEMBL20625249 | 0.81 | EPHX2 (0.62) | DNM1EPHX2S1PR2S1PR1S1PR3 | |
| SCHEMBL11634642 | 0.81 | EPHX2 (0.62) | DNM1EPHX2S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1514727-A | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to progression of disease in patients with prostate cancer | ���Ͽع�����˾ | 2004-07-21 | — | — | CN | disclosed |
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |
| CN-1048484-C | A process for preparing a composition containing benzoheterocycles | OTSUKA PHARMA CO LTD (JP) | 2000-01-19 | — | — | CN | disclosed |
| US-5658926-A | ANTICOAGULANTS, ANTIHISTAMINES, ANTIARRHYTHMIC, CARTIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5506239-A | Carbostyril derivative and platelets aggregation inhibitory agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| CN-1107146-A | A process for preparing a composition containing benzoheterocycles | OTSUKA PHARMA CO LTD (JP) | 1995-08-23 | — | — | CN | disclosed |
| CN-1027505-C | Process for preparing benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | disclosed |
| EP-0569592-A1 | CARBOSTYRIL DERIVATIVE AND PLATELET AGGLUTINATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-18 | — | — | EP | disclosed |
| CN-1051038-A | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1991-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | DNM1 2525/4885EPHX2 4249/4885S1PR2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.